Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: A brief report

Journal of Thoracic Oncology

Volumn 5, Issue 4, 2010, Pages 554-557

  Lind, Joline S W ^a   Postmus, Pieter E ^a   Smit, Egbert F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Erlotinib; Non small cell lung cancer; Osteoblastic response

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE;

ADULT; ARTICLE; BONE DENSITY; BONE LESION; BONE METASTASIS; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL FEATURE; DISEASE COURSE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; OSTEOBLAST; OSTEOLYSIS; OSTEOSCLEROSIS; PRIORITY JOURNAL;

EID: 77950970525     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d3e47e     Document Type: Article

References (15)

1. Napoli LD, Hansen HH, Muggia FM, et al. The incidence of osseous involvement in lung cancer, with special reference to the development of osteoblastic changes. Radiology 1973;108:17-21.
2. Coleman RE, Mashiter G, Whitaker KB, et al. Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med 1988;29: 1354-1359.
3. Vogel CL, Schoenfelder J, Shemano I, et al. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 1995;13:1123-1128.
4. Schneider JA, Divgi CR, Scott AM, et al. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med 1994;35:1748-1752. (Pubitemid 24346792)
5. Janicek MJ, Hayes DF, Kaplan WD. Healing flare in skeletal metastases from breast cancer. Radiology 1994;192:201-204. (Pubitemid 24191545)
6. Cosolo W, Morstyn G, Arkles B, et al. Flare responses in small cell carcinoma of the lung. Clin Nucl Med 1988;13:13-16. (Pubitemid 18034409)
7. Stattaus J, Hahn S, Gauler T, et al. Osteoblastic response as a healing reaction to chemotherapy mimicking progressive disease in patients with small cell lung cancer. Eur Radiol 2009;19:193-200.
8. Muggia FM, Hansen HH. Osteoblastic metastases in small-cell (oat-cell) carcinoma of the lung. Cancer 1972;30:801-805.
9. Lemieux J, Guimond J, Laberge F, et al. The bone scan flare phenomenon in non-small-cell lung cancer. Clin Nucl Med 2002;27: 486-489. (Pubitemid 35190369)
10. Krupitskaya Y, Eslamy HK, Nguyen DD, et al. Osteoblastic bone flare on F18-FDG PET in non-small cell lung cancer (NSCLC) patients receiving bevacizumab in addition to standard chemotherapy. J Thorac Oncol 2009;4:429-431.
11. Garfield D. Increasing osteoblastic lesions as a manifestation of a major response to gefitinib. J Thorac Oncol 2006;1:859-860. (Pubitemid 47181394)
12. Garfield D, Zampa G, Cadranel J, et al. Effects of gefitinib (G) on bone metatases (BMs) in non-small cell lung cancer patients. J Clin Oncol (Meeting Abstracts) 2006;17147.
13. Chao HS, Chang CP, Chiu CH, et al. Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib. Clin Nucl Med 2009;34:346-349.
14. Lind JSW, Postmus PE, Heideman DA, et al. Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity. J Thorac Oncol 2009;4:1585-1856.
15. Garfield D, Cadranel J, Normanno N. Osteoblastic metastases in nonsmall cell lung cancer and its possible significance. Lung Cancer 2008;60:146-147.